Virtus LifeSci Biotech Clinical Trials ETF Rating $49.91 -1.60 (-3.11%) Closing price 09/10/2026 04:10 PM EasternExtended Trading$50.47 +0.56 (+1.12%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.73Holdings in BBC have an aggregate rating of Moderate Buy based on 279 analyst ratings issued in the past year covering 25 companies (26.9% of the portfolio).BBC Aggregate Price Target$49.91High Prediction$49.91Average Prediction$49.91Low Prediction$49.91Holdings in BBC have an aggregate price target of $49.91 and a range of $49.91 to $49.91 covering 25 companies (26.9% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.48%AMLXAmylyx Pharmaceuticals$32.09-1.0%3.8414 of 5 stars3.00$36.50 13.7%11Positive News1.47%TRAXFirst Tracks Biotherapeutics$37.98-4.0%2.7723 of 5 stars2.73$63.00 65.9%111.34%ABCLAbCellera Biologics$10.46-5.3%3.304 of 5 stars2.71$12.83 22.7%7Positive NewsGap Down1.31%XNCRXencor$24.26-2.7%2.5575 of 5 stars2.67$30.71 26.6%9Positive News1.16%MNPRMonopar Therapeutics$109.96-2.2%1.7823 of 5 stars2.86$118.67 7.9%14Positive NewsAnalyst Forecast1.15%ATAIAtai Beckley$7.35+0.8%3.0064 of 5 stars2.06$10.56 43.6%16News CoveragePositive NewsOptions Volume1.10%MBXMBX Biosciences$60.94-3.1%3.0512 of 5 stars2.77$77.00 26.4%13Positive News1.10%QUREuniQure$44.47-3.3%3.5225 of 5 stars2.76$65.00 46.2%171.08%REPLReplimune Group$13.24-8.4%1.8307 of 5 stars2.60$12.00 -9.4%101.05%SLSSELLAS Life Sciences Group$13.49-3.3%0.368 of 5 stars2.33$10.00 -25.9%3Gap Down1.04%LBRXLB Pharmaceuticals$46.25-3.0%1.3922 of 5 stars2.80$49.63 7.3%101.03%DFTXDefinium Therapeutics$37.73-0.7%2.7871 of 5 stars3.00$63.00 67.0%201.03%FDMT4D Molecular Therapeutics$13.49-4.9%3.516 of 5 stars2.80$29.63 119.6%10Gap Down1.02%IMMXImmix Biopharma$12.70+3.2%3.5552 of 5 stars2.78$21.29 67.6%9Positive News1.01%ANROAlto Neuroscience$31.73-6.9%1.8364 of 5 stars2.64$37.25 17.4%110.99%ORICOric Pharmaceuticals$12.07-3.4%2.588 of 5 stars2.79$19.60 62.4%14Positive News0.98%CGEMCullinan Therapeutics$21.00-1.5%3.1428 of 5 stars2.78$32.86 56.5%9News CoverageInsider Trade0.98%ZBIOZenas BioPharma$31.10-3.7%1.9452 of 5 stars2.56$45.71 47.0%90.98%VORVor Biopharma$22.34-3.9%1.7755 of 5 stars2.82$43.38 94.2%110.96%NRIXNurix Therapeutics$25.81-1.7%2.9628 of 5 stars2.80$34.21 32.6%15Positive News0.95%CADLCandel Therapeutics$11.33-6.9%3.3011 of 5 stars2.64$19.29 70.2%110.93%IMNMImmunome$24.97-4.4%3.0996 of 5 stars2.85$34.64 38.7%13Positive NewsAnalyst Forecast0.92%ASMBAssembly Biosciences$30.46-7.3%4.0658 of 5 stars2.88$45.60 49.7%8Trending NewsAnalyst Revision0.91%ACHVAchieve Life Sciences$7.28-3.4%3.0137 of 5 stars3.00$15.00 106.0%8Gap Down0.91%SANASana Biotechnology$3.09-2.5%2.7296 of 5 stars2.80$9.33 202.0%10News Coverage This page (NYSEARCA:BBC) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
